On the putative physiological role of allopregnanolone on GABA(A) receptor function.
To obtain definitive evidence for a physiological allosteric modulatory role for endogenous brain ALLO on GABA(A) receptor function, we studied GABA(A) receptor activity under conditions in which the concentration of endogenous brain ALLO was decreased by about 80% for longer than 5 h following the administration of SKF 105111- 17beta-17-[bis (1methylethyl) amino carbonyl] androstane-3,5-diene-3-carboxylic acid (SKF), a potent inhibitor of 5alpha-reductases Type I and II. We used the in situ patch-clamp technique to record GABA-evoked currents and spontaneous inhibitory postsynaptic currents (sIPSCs) from pyramidal neurons in neocortical slices of vehicle- or SKF-treated mice. The potency, but not the efficacy, of exogenously applied GABA was decreased in slices from mice treated with SKF. When neocortical slices were treated in vitro for 3 h with 10 microM SKF, ALLO was also reduced (25-30%) and in addition, the GABA dose-response curve was shifted to the right; however this shift was not as marked as the shift in the slices obtained from mice treated with SKF, in keeping with the smaller decrease of the ALLO content in these slices. Furthermore, direct application of ALLO to these slices shifted the dose-response curve of GABA back toward a non-SKF treated profile. We then analyzed GABAergic sIPSCs in neocortical slices obtained from vehicle or SKF-treated mice. Mean decay time and charge transfer were significantly reduced by SKF treatment. The decay of sIPSCs was best fitted by two exponentials, but only the fast component was decreased in the SKF group. Direct application of ALLO (100 nM) normalizes the sIPSC kinetics in slices from ALLO depleted mice. No changes were detected in the amplitude or frequency of sIPSCs. These data demonstrate that endogenous ALLO physiologically regulates spontaneously induced Cl(-) current by acting on a specific recognition site, which is probably located on GABA(A) receptors (a receptor on a receptor), thereby prolonging inhibitory currents by facilitating conformational transition of the GABA-gated Cl(-) channel to an open state.
Puia
G
G
The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 W. Taylor St. MC912, Chicago, IL 60612, USA.
Mienville
J-M
JM
Matsumoto
K
K
Takahata
H
H
Watanabe
H
H
Costa
E
E
Guidotti
A
A
D058891:5-alpha Reductase Inhibitors; D000494:Allosteric Regulation; D000731:Androstanes / Q000494:pharmacology; D000818:Animals; D018118:Chloride Channels / Q000187:drug effects / Q000502:physiology; D018682:GABA Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D019579:Neocortex / Q000187:drug effects / Q000378:metabolism; D018408:Patch-Clamp Techniques; D011280:Pregnanolone / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology*; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology
D058891:5-alpha Reductase Inhibitors; D000731:Androstanes; D018118:Chloride Channels; D018682:GABA Agents; D011963:Receptors, GABA-A; C473295:SKF 105111; D005680:gamma-Aminobutyric Acid; D011280:Pregnanolone